Gilead Sciences, Inc.

AbbVie is taking a deep dive into CAR-T therapies for autoimmune diseases with its acquisition of privately owned Capstan Therapeutics for up to $2.1bn, an investment that both bolsters its autoimmune

The US Food and Drug Administration’s decision to remove Risk Evaluation and Mitigation Strategies (REMS) requirements for CAR-T cell therapies and streamline patient monitoring will likely expand the

The US Food and Drug Administration’s elimination of the Risk Evaluation and Mitigation Strategies (REMS) for all currently approved BCMA- and CD-19-directed autologous chimeric antigen receptor (CAR)

Who: Kymera Therapeutics with Gilead Sciences What: On June 25, Kymera announced a deal with Gilead for molecular glue degraders targeting CDK2. Why: While potent anti-cancer drugs, traditional C